Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes.
By targeting tissue-specific regulatory mechanisms, we have discovered tissue selective compounds and successfully optimized hits in all of our internal discovery programs: Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), and Oncology (C-Myc translation inhibitors).
The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes.
By targeting tissue-specific regulatory mechanisms, we have discovered tissue selective compounds and successfully optimized hits in all of our internal discovery programs: Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), and Oncology (C-Myc translation inhibitors).
The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Lung Fibrosis - Collagen I translation inhibitors
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
